Predictors of health-related quality of life in patients with Crohn’s disease receiving biological therapy

Research output: Contribution to journalJournal articleResearchpeer-review


Background and Aim: Health-related quality of life (HRQoL) is impaired in patients with Crohn’s disease (CD). This study aimed to identify the impact of clinical disease activity on HRQoL in CD patients treated with biological agents. Methods: Patients with moderate to severe active CD treated with biological agents in Denmark were included from 2016–2018. Disease related symptoms were assessed via the Harvey Bradshaw Index. HRQoL was measured on the Short Health Scale (SHS). Multivariable linear regression models were conducted separately for each SHS item and average SHS score stratified for sex, adjusting for clinical manifestation and age. Results: In total, 1,181 CD patients were included. The mean age was 33 years and 56% were women. Abdominal pain (range of regression coefficients 1.18–1.42), number of liquid stools (0.33–0.58), and the appearance of a new rectal fistula (0.91–1.32) affected all domains in the SHS negatively for men and women. Arthralgia (0.47–0.67) and abdominal mass (0.54–0.62) affected 4 out of 5 items on SHS negatively for women and men, respectively. Female sex was found a predictor of lower HRQoL across all SHS items, whereas age and fistulizing disease, as phenotype, were not associated with lower HRQoL. Conclusions: Abdominal pain, number of liquid stools, a new rectal fistula, arthralgia for women, clinically assessed abdominal mass for men as well as female sex, were all found to be predictors of decreased HRQoL.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Issue number12
Pages (from-to)1434-1441
Publication statusPublished - Dec 2021


  • Crohn’s disease
  • Harvey Bradshaw index
  • Health-related quality of life
  • biological treatment
  • clinical activity indices
  • epidemiology
  • short health scale


Dive into the research topics of 'Predictors of health-related quality of life in patients with Crohn’s disease receiving biological therapy'. Together they form a unique fingerprint.

Cite this